PMC2918834_01
Disease response to Bevacizumab therapy. a CA19-9 biomarker response to Bevacizumab therapy in patient 1 (i) and patient 2 (ii), respectively. Light gray bars indicate administration of single agent Bevacizumab. Dark gray bar indicates administration of Bevacizumab and carboplatinum. The timing of serial CT scans shown in b are indicated with asterisks. b CT scan of patient 2 with serial scans demonstrating disease state after the first course of Bevacizumab therapy (left panels), evidence of progression after discontinuation of therapy (middle panels) and stabilization of disease with re-initiation of therapy (right panels). Boxes indicate representative splenic lesion. The arrow indicates increased ascites at the time of recurrence which significantly resolved with re-initiation of therapy.
cro0003-0001-f01.jpg
PMC2918834_02_cro0003-0001-f01.jpg
F1
After successive cycles of therapy, the CA19-9 decreased to 180 and the patient reported significant symptom improvement (fig. 1aii).
PMC2918834_02
Disease response to Bevacizumab therapy. a CA19-9 biomarker response to Bevacizumab therapy in patient 1 (i) and patient 2 (ii), respectively. Light gray bars indicate administration of single agent Bevacizumab. Dark gray bar indicates administration of Bevacizumab and carboplatinum. The timing of serial CT scans shown in b are indicated with asterisks. b CT scan of patient 2 with serial scans demonstrating disease state after the first course of Bevacizumab therapy (left panels), evidence of progression after discontinuation of therapy (middle panels) and stabilization of disease with re-initiation of therapy (right panels). Boxes indicate representative splenic lesion. The arrow indicates increased ascites at the time of recurrence which significantly resolved with re-initiation of therapy.
cro0003-0001-f01.jpg
PMC2918834_02_cro0003-0001-f01.jpg
F1
After successive cycles of therapy, the CA19-9 decreased to 180 and the patient reported significant symptom improvement (fig. 1aii).